Biocon Limited has informed the Exchange regarding Outcome of Board Meeting held on May 07, 2026.
BIOCON · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Biocon's Board approved audited financial results for Q4 and FY2026, recommended a final dividend of Rs. 0.50 per share (10% on Rs. 5 face value) with record date July 3, 2026. The Board changed statutory auditors from B S R & Co. LLP to S. R. Batliboi & Associates LLP for 5 years. Six new directors are being appointed including pharma veterans Rajiv Malik (former Viatris/Mylan President) and Daniel Bradbury (former Amylin CEO), along with global health expert Peter Baron Piot. The Board approved acquiring the remaining ~2% stake in subsidiary Biocon Biologics Limited (BBL) through a share swap: issuing 87.92 lakh Biocon shares at Rs. 376.16 per share (total Rs. 330.73 crore) to 127 BBL shareholders, taking BBL ownership to ~99.99%. OCDs worth Rs. 1,698 crore and CCDs worth Rs. 473.4 crore in BBL will also convert to equity. A new Long-Term Incentive Plan 2026 was approved. The 48th AGM is scheduled for August 6, 2026.
The BBL full integration via share swap simplifies corporate structure and could unlock value for shareholders. The diverse, high-profile board appointments bring global pharma and healthcare expertise. Dividend reinforces shareholder returns while the incentive plan helps retain key talent. The preferential issuance will dilute existing shareholders by ~0.87%.